The Impact of a Community-Oriented Problem-Based Learning Curriculum Reform on the Quality s6

STROBE Statement—Checklist of items that should be included in reports of cohort studies Item Check No Recommendation Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or  the abstract (b) Provide in the abstract an informative and balanced summary of what  was done and what was found Introduction Background/rationale 2 Explain the scientific background and rationale for the investigation  being reported Objectives 3 State specific objectives, including any prespecified hypotheses  Methods Study design 4 Present key elements of study design early in the paper  Setting 5 Describe the setting, locations, and relevant dates, including periods of  recruitment, exposure, follow-up, and data collection Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection  of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed N.A. and unexposed Variables 7 Clearly define all outcomes, exposures, predictors, potential  confounders, and effect modifiers. Give diagnostic criteria, if applicable Data sources/ 8* For each variable of interest, give sources of data and details of methods measurement of assessment (measurement). Describe comparability of assessment  methods if there is more than one group Bias 9 Describe any efforts to address potential sources of bias  Study size 10 Explain how the study size was arrived at  Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If  applicable, describe which groupings were chosen and why Statistical methods 12 (a) Describe all statistical methods, including those used to control for  confounding (b) Describe any methods used to examine subgroups and interactions  (c) Explain how missing data were addressed  (d) If applicable, explain how loss to follow-up was addressed N.A. (e) Describe any sensitivity analyses N.A. Results Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included  in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage N.A. (c) Consider use of a flow diagram  Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical,  social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable  of interest (c) Summarise follow-up time (eg, average and total amount)  Outcome data 15* Report numbers of outcome events or summary measures over time  Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted  estimates and their precision (eg, 95% confidence interval). Make clear

1 which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were  categorized (c) If relevant, consider translating estimates of relative risk into N.A. absolute risk for a meaningful time period Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions,  and sensitivity analyses Discussion Key results 18 Summarise key results with reference to study objectives  Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any  potential bias Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and  other relevant evidence Generalisability 21 Discuss the generalisability (external validity) of the study results  Other information Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present  article is based

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.